Arbutus Biopharma

Arbutus Biopharma

Founded in 2007 through the merger of Protiva Biotherapeutics and Tekmira Pharmaceuticals, Arbutus Biopharma became a public company headquartered in Warminster, Pennsylvania. The firm was shaped by the early work of scientists who helped invent the modern LNP delivery system, which encapsulates mRNA and other nucleic acid drugs for delivery into cells. Dr. Michael J. McElhaugh assumed the role of interim President and CEO in November 2023, succeeding William Collier. Arbutus's IP estate comprises more than 100 granted US patents and pending applications, with coverage extending into the 2030s for key LNP formulations used in commercially approved messenger RNA products. The firm's economic model rests on two pillars: a wholly-owned chronic hepatitis B virus (HBV) pipeline and a broad patent portfolio licensed to global pharmaceutical companies. Arbutus is developing imdusiran (AB-729), an RNAi therapeutic designed to suppress all HBV surface antigens, currently in Phase 2 trials. It is partnered with Assembly Biosciences on next-generation oral HBV candidates. The licensing and litigation arm has been historically contentious: Arbutus successfully defended its US Patent No. 8,058,069 against Moderna's validity challenge in 2020, and a subsequent patent trial against Moderna and Pfizer is scheduled for 2026 in the US District Court for the District of Delaware. Earlier settlements include a 2015 agreement resolving all claims with Alnylam Pharmaceuticals and a 2018 licensing deal with Gritstone bio. Arbutus operates with roughly 97 full-time employees across its Pennsylvania headquarters and a research facility in Burnaby, British Columbia, Canada. As of September 2024, the firm reported $123.7 million in cash, cash equivalents and investments, which management estimates funds operations into the first half of 2026. The firm also receives milestone and royalty payments tied to its partners' progress. In 2023, Arbutus terminated its collaboration with Antios Therapeutics following that company's bankruptcy filing, reclaiming full rights to certain HBV assets. There is no adjacent family office or wealth management vehicle; the firm is a standard Delaware corporation trading on Nasdaq. Arbutus is structurally unusual among micro-cap biotechs because its corporate viability does not depend solely on clinical data readouts. The IP monetization stream — combining up-front license fees, milestone payments, and damage claims from ongoing patent litigation — creates a funding mechanism decoupled from equity capital markets. This dual-track model, where a pipeline is subsidized by a legal and licensing division, makes Arbutus resemble an operating company with an embedded royalty trust, distinct from pure-play clinical-stage peers.